⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
VIJAYA - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.5
| Stock Code | VIJAYA | Market Cap | 9,713 Cr. | Current Price | 939 ₹ | High / Low | 1,180 ₹ |
| Stock P/E | 60.9 | Book Value | 82.3 ₹ | Dividend Yield | 0.21 % | ROCE | 20.2 % |
| ROE | 18.1 % | Face Value | 1.00 ₹ | DMA 50 | 980 ₹ | DMA 200 | 997 ₹ |
| Chg in FII Hold | -3.17 % | Chg in DII Hold | 3.26 % | PAT Qtr | 44.2 Cr. | PAT Prev Qtr | 42.7 Cr. |
| RSI | 40.5 | MACD | -14.6 | Volume | 3,73,801 | Avg Vol 1Wk | 1,43,843 |
| Low price | 800 ₹ | High price | 1,180 ₹ | PEG Ratio | 9.20 | Debt to equity | 0.40 |
| 52w Index | 36.7 % | Qtr Profit Var | 31.8 % | EPS | 15.5 ₹ | Industry PE | 32.6 |
📊 Financial Overview
- Revenue & Profitability: Quarterly PAT improved slightly (44.2 Cr. vs 42.7 Cr.), showing stability. EPS at 15.5 ₹ is moderate.
- Margins & Returns: ROCE at 20.2% and ROE at 18.1% indicate strong efficiency and shareholder returns.
- Debt: Debt-to-equity ratio of 0.40 is relatively high compared to peers, raising leverage concerns.
- Cash Flow: Supported by profitability, but debt levels may pressure liquidity in downturns.
💹 Valuation
- P/E Ratio: 60.9 vs Industry PE of 32.6 → Overvalued relative to peers.
- P/B Ratio: Current Price 939 ₹ vs Book Value 82.3 ₹ → High premium.
- PEG Ratio: 9.20 → Expensive relative to growth prospects.
- Intrinsic Value: Current price trades above fair value, limited margin of safety.
🏢 Business Model & Competitive Advantage
- Strong presence in healthcare diagnostics with established brand recognition.
- High ROCE and ROE reflect efficient capital utilization.
- Dividend yield of 0.21% adds minor shareholder value.
📈 Technicals & Entry Zone
- RSI at 40.5 → Near oversold territory, potential accumulation zone.
- MACD negative (-14.6) → Weak momentum, short-term caution advised.
- Entry Zone: Attractive accumulation between 900–930 ₹.
- Long-Term Holding: Suitable for investors seeking healthcare exposure, but valuation risks remain.
✅ Positive
- Strong ROCE and ROE indicate efficient capital use.
- DII holdings increased by 3.26%, showing strong domestic institutional support.
- Quarterly PAT growth shows resilience in earnings.
⚠️ Limitation
- High P/E and PEG ratios suggest overvaluation.
- Debt-to-equity ratio of 0.40 raises financial risk.
- Weak technical momentum with negative MACD.
📉 Company Negative News
- FII holdings decreased by 3.17%, showing reduced foreign investor confidence.
- Stock has fallen significantly from its 52-week high of 1,180 ₹ to current levels.
📈 Company Positive News
- DII holdings increased by 3.26%, reflecting strong domestic institutional support.
- Quarterly PAT improved slightly, showing earnings stability.
- 52-week performance up 36.7%, reflecting investor confidence despite volatility.
🏭 Industry
- Industry PE at 32.6 suggests sector trades at lower multiples.
- VIJAYA commands premium valuation due to brand strength, but debt and high multiples limit attractiveness.
🔎 Conclusion
VIJAYA demonstrates strong fundamentals with high ROCE and ROE, supported by institutional confidence. However, high debt levels and stretched valuations compared to industry peers raise caution. Entry is favorable near 900–930 ₹ for long-term investors seeking healthcare exposure, but short-term momentum remains weak. Suitable as a long-term hold for those confident in the sector’s growth, though valuation and leverage risks must be considered.